Clinical trials: Haematological Malignancies
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Oncology, Haematological Malignancy
Central Venous Access Device Removal in Cancer Patients
Background: Central venous catheters are frequently used during cancer treatment with the aim of venepreservation. It can facilitate venous access for the safe administration of irritating or vesicant intravenous cancer…
- Trial name
- NCT03855969
- Testing
- Removal of a central venous access device
- Where
- Belgium
- Volunteers
- 1,402 people
- Sponsor
- General Hospital Groeninge
Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
Paediatric patients affected by haematological malignancies and eligible to undergo HSCT from an unrelated volunteer will be stratified according to the degree of compatibility with their donor, the source of haematopoietic stem…
- Trial name
- ATG FRES (NCT00934557)
- Testing
- ATG Fresenius
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hematological Malignancy
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
The trial is designed as an early exploratory single-centre, open, single-arm clinical trial. The trial is planned to evaluate the safety and efficacy of CAR-T for the treatment of relapsed refractory malignant haematological…
- Trial name
- NCT06238336
- Testing
- CAR-T cell therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanxi Bethune Hospital
Cancer
Pharmacogenetics of VOD in Children With HSCT
This project aims to identify common pharmacogenetic biomarkers predisposing children with cancer to develop hepatic VOD during their cancer treatment including HSCT.
- Trial name
- MVO (NCT03664427)
- Where
- France
- Volunteers
- 436 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukaemia, Lymphoma
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder…
- Conditions
- Leukaemia, Lymphoma, Other Haematological Diseases
- Trial name
- MAC UCBT (NCT02310997)
- Testing
- Umbilical Cord Blood Transplant, Cyclophosphamide, Total body irradiation
- Where
- 12 sites in United Kingdom
- Volunteers
- 11 people
- Sponsor
- University College, London
Haematological Malignancy, Acute Leukemia
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
To date, allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes, haemoglobinopathies…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT04331483)
- Testing
- Physical activity program
- Where
- France
- Sponsor
- Centre Leon Berard
Haematological Malignancy
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
To evaluate the impact of innovative molecular diagnostics on the clinical management of patients with haematological malignancies via updated Appropriate-Prescribing-Guides including Next-Generation Sequencing (NGS) panels…
- Trial name
- NCT03750994
- Where
- 26 sites in France
- Volunteers
- 3,960 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Haematological Malignancies
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.
- Trial name
- ICAT (NCT01827579)
- Testing
- CD25/71 allodepleted donor T-cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- University College, London
Allogeneic Stem Cell Transplantation
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
The allogeneic hematopoietic stem cell marrow is the only curative treatment for many hematologic malignancies. However, many patients relapse in these situations to be therapeutic possibilities scarce and mixed.
- Trial name
- NCT01212796
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Solid Tumour, Malignant Haematological Tumour
Nivestim™ in Treatment of Malignant Diseases
The purpose of this study is to observe the tolerability, safety and efficacy of preventative treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.
- Conditions
- Solid Tumour, Malignant Haematological Tumour, Primary or Secondary Prophylactic Treatment
- Trial name
- NCT01627990
- Where
- 48 sites in Germany
- Volunteers
- 386 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Hematological Malignancies
An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation
The 'Open Window' Study is a prospective longitudinal study using a 4 group randomised control trial design to evaluate the psychological effect of 'Open Window' on the consequences of long term isolation on patients undergoing…
- Trial name
- NCT00348959
- Testing
- 'Open Window' Project
- Where
- Ireland
- Volunteers
- 198 people
- Sponsor
- St. James's Hospital, Ireland
Cancer, Oncology
Seen and Be Heard: Ensuring Fair Cancer Care for All Children
Introduction: Research has routinely been conducted into the experiences and well-being of children and young people with cancer and their families.
- Conditions
- Cancer, Oncology, Haematological Malignancy
- Trial name
- NCT06481527
- Volunteers
- 50 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Solid Tumour
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation.
- Trial name
- DETERMINE (NCT05722886)
- Testing
- Alectinib, Atezolizumab, Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 825 people
- Sponsor
- Cancer Research UK
Diffuse Large B Cell Lymphoma
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large…
- Trial name
- REMoDL-A (NCT04546620)
- Testing
- R-CHOP, R-CHOP + acalabrutinib
- Where
- 33 sites in United Kingdom
- Volunteers
- 453 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Hematopoietic/Lymphoid Cancer
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of abnormal cells.
- Trial name
- NCT00959231
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Haematological Abnormality
The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally
- Trial name
- NCT01936064
- Testing
- Jobelyn + Cyclophosphamide-Epirubicin6
- Where
- 2 sites in Nigeria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lagos State University